Abstract: A 38-year-old male patient presented with scaly plaques on the scalp and lower extremities for 8 years, which worsened with generalized involvement of scales for 16 months. The body surface area (BSA) of the lesions was 80% and the psoriasis area and severity index (PASI) score was 32.5. Pre-treatment screening for biological therapy revealed anti-hepatitis C virus (HCV) antibody 14.56 S/CO, and high-sensitivity HCV-RNA quantitation 1.95×10⁶ IU/mL. After 1 month of anti-HCV treatment with oral sofosbuvir/velpatasvir tablets and Ganshuang Granules, the patient's high-sensitivity HCV-RNA quantitation turned negative. Following a multidisciplinary consultation, secukinumab therapy was initiated. At 20 weeks of treatment, PASI 100 was achieved; after 6 months of secukinumab treatment, the patient's psoriasis showed no recurrence, and there were no signs of HCV reactivation.

Key words: psoriasis, secukinumab, hepatitis C